- €14.52m
- €10.72m
- €13.19m
Brief: Biofrontera AG Says Legal Dispute On Import In USA Will Result In Revised Outlook
Brief: Biofrontera AG Resolves Capital Increase From Authorized Capital
Brief: Biofrontera AG Says Plans Capital Reduction And Considers Subsequent Capital Increase From Authorized Capital
Brief: Biofrontera AG Says FY 2022 Total Revenue Amounted To EUR 25.7 Million
Brief: Biofrontera AG Says Going To Submit Proposal For Resolution On Capital Increase
Brief: Biofrontera Says Appointed Pilar De La Huerta As New Chief Financial Officer With Effect As Of 12 Sept. 2022
Brief: Biofrontera Reports Total Sales Of EUR 15,076 Thousand In Period From January 1 To June 30, 2022
German stocks - Factors to watch on August 15
Brief: Biofrontera AG Has Dismissed And Terminated Chief Financial Officer, Ludwig Lutter
Brief: Biofrontera AG Management Board And Supervisory Board Jointly Recommend Not To Accept The Takeover Offer Of Deutsche Balaton AG
Brief: Biofrontera AG Says Will Terminate Its U.S. ADS Program
Brief: Biofrontera Q1 EBITDA At EUR 1.3 Mln
Biofrontera AG expected to post a loss of 9 cents a share - Earnings Preview
Brief: Biofrontera AG Expects Increasing Revenues A Positive EBITDA And EBIT In Low Single-Digit Mln Range From 2023
Brief: Biofrontera Shifts Publication Of Annual Report 2021 To April 29, 2022
Brief: Biofrontera Prelim FY Total Revenue Down At EUR 28.8 Mln
Brief: Biofrontera - Governmental Price Decree For Ameluz® Withdrawn In Spain
Brief: Biofrontera Statement On The Open Letter Of Maruho Deutschland
RCS - Maruho Deutschland - Extraordinary General Meeting on 7 April 2022